NCT07292207 2025-12-18
ARCHE
Nagoya City University
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT05559164 2025-11-14
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT05392608 2025-09-17
SEQUEL-Breast
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT06033092 2025-08-28
TOLERANT
European Institute of Oncology
Phase 2 Active not recruiting
NCT06150898 2025-06-13
KePreSt
Jules Bordet Institute
Phase 2 Recruiting
NCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT06229067 2024-01-29
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT02897050 2022-04-20
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Suspended
NCT04389073 2022-02-25
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT03024580 2019-08-15
MEGA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT03405168 2018-11-16
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed